Sage's Zulresso Launch Is Off, But Not Running
Executive Summary
The company updated investors on the launch of the first treatment for postpartum depression during its Q2 earnings call. More than 100 sites have been certified under the REMS.
You may also be interested in...
Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.